OABI Insider Trading

Insider Ownership Percentage: 8.60%
Insider Buying (Last 12 Months): $1,356,312.50
Insider Selling (Last 12 Months): $458,129.12

OmniAb Insider Trading History Chart

This chart shows the insider buying and selling history at OmniAb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$82ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

OmniAb Share Price & Price History

Current Price: $1.93
Price Change: Price Increase of +0.08 (4.32%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for OABI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$1.93Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for OmniAb (NASDAQ:OABI)

72.08% of OmniAb stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OABI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$116ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal InflowsTotal Outflows
OmniAb logo
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Read More on OmniAb

Today's Range

Now: $1.93
Low: $1.82
High: $1.94

50 Day Range

MA: $2.99
Low: $1.85
High: $3.88

52 Week Range

Now: $1.93
Low: $1.81
High: $5.25

Volume

851,877 shs

Average Volume

559,772 shs

Market Capitalization

$235.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.06

Who are the company insiders with the largest holdings of OmniAb?

OmniAb's top insider investors include:
  1. Matthew W Foehr (CEO)
  2. John L Higgins (Director)
  3. Charles S Berkman (Insider)
  4. Kurt A Gustafson (CFO)
Learn More about top insider investors at OmniAb.

Who are the major institutional investors of OmniAb?

OmniAb's top institutional investors include:
  1. Woodstock Corp — 0.61%
Learn More about top institutional investors of OmniAb stock.

Which major investors are selling OmniAb stock?

Within the previous quarter, OABI stock was sold by these institutional investors:
  1. Woodstock Corp
Within the last year, company insiders that have sold OmniAb company stock include:
  1. Matthew W Foehr (CEO)
  2. John L Higgins (Director)
  3. Charles S Berkman (Insider)
Learn More investors selling OmniAb stock.